Ein neuer Tenbagger (Aktien ab 1000% Performance) scheint geboren - Mazal Plant Pharmaceuticals Inc. !
Mazal Plant hat einen neuartigen pflanzlichen Wirkstoff mit Namen MAHDL entwickelt, durch den die Cholesterinwerte im Blut positiv verändert werden und mit dem Venen- und Herzkrankheiten vorgebeugt bzw geheilt werden können, die durch einen unnatürlichen Cholesterinspiegel entstehen.
Mit Cholesterinmitteln werden weltweit jährlich etwa 23 Milliarden Dollar umgesetzt. Ein riesiger Markt also.
WKN: A0JMAW KÜRZEL: M9J
Press Release |
|
Mazal Plant Pharmaceutical's Investigational New Drug Application Approved for Botanical HDL Cholesterol Elevating Drug, MAHDL
Tuesday August 8, 6:00 pm ET
Company to Begin Clinical Trials Once Clinical Sites Are Identified and Approved
NEW YORK, NY--(MARKET WIRE)--Aug 8, 2006 -- Mazal Plant Pharmaceuticals Inc. (Other OTC:MZPP.PK - News) (Frankfurt:M9J.F - News) ("Mazal") announced that based on the approval that it previously received from the FDA for its HDL elevating drug, MAHDL, it is now negotiating with clinical sites to use the company's common stock as partial payment for the study in order to conserve working capital for other corporate requirements.
Mazal Plant Pharmaceuticals has been approved to conduct a large-scale double-blind, 4-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be given either MAHDL, placebo, Statin + Placebo or MAHDL+ Statin for 4 months and tested for changes in HDL, LDL, Cholesterol, Triglycerides and CRP serum levels.
About Mazal Plant Pharmaceuticals Inc.
Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.
Additional information on Mazal Plant Pharmaceuticals, Inc. may be found at: http://www.mazal.cc/index.html.
Forward-Looking Statements
"Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements Mazal Plant Pharmaceuticals Inc., to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
CONTACT: LC Group Rick Lutz (404) 261-1196
Die heiße Phase für klinische Test beginnt in Kürze. Man verhandelt schon mit geeigneten Kliniken darüber. Hier könnten also schon bald gute News anstehen!
Eins spannender neuer und unentdeckter Biotechwert also, den man beobachten sollte.
&a=A0JMAW&zeitraum=9&bname=&ind_news_art=&zeitvon=&bis=1163541913.48482&typ=3&skalierung=dec&zeitbis=&beingabe=Name%2C%20WKN%2C%20ISIN&ind_volume=ON&cookies=HASH(0xb70f1b4)&boerse_id=1&ago=Aktualisieren&go=go&von=0&banner_ref=HASH(0xb3f9ac8)&req_host=www.ariva.de&b=&ind_gd38=ON)
